STOCK TITAN

Exicure flags going-concern doubt with $1.23M in cash

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Exicure, Inc. reported no revenue and a $2.307 million net loss for the nine months ended September 30, 2026, compared with a $2.048 million loss a year earlier. Third-quarter net income was $642,000, including a $724,000 gain on settlement of a milestone liability using shares and a $688,000 contingent-consideration fair-value gain. Cash was $1.225 million at September 30; management said it was insufficient to fund the next 12 months and reported substantial doubt about the company’s ability to continue as a going concern.

A material weakness remains in internal controls over financial reporting, and management is developing remediation. Stockholders’ equity was $1.895 million at September 30, below Nasdaq’s $2.5 million minimum; Nasdaq gave the company until December 2, 2026, to complete its plan and publicly demonstrate compliance. Exicure agreed to sell GPC-100 assets to GPCRT for KRW 6,500,000,000 (approximately $4.810 million), subject to closing conditions; the interim payment had not been received as of issuance, and the parties were negotiating revisions. A separate agreement contemplates Exicure acquiring 20% to 100% of NeuroQ for newly issued shares, with up to $500,000 in development funding after closing, subject to agreement on terms, due diligence and approvals.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 3 points

How the balance works

Positive

  • Moderate pointNine-month operating cash use fell to $2.521 million; 2025: $7.408 million.

Negative

  • Major pointCash of $1.225 million was insufficient for 12 months after issuance.
  • Major pointMaterial weakness in controls remained as of September 30, 2026.
  • Moderate pointNine-month net loss rose 13% to $2.307 million.

Filing Explained

Exicure issued 172,058 common shares on July 31, 2026, to settle the GPCR Phase 2 milestone; the shares were included in the 6,545,995 outstanding at September 30, increasing the share count and reducing existing holders’ ownership percentages, absent offsets.

Revenue $0 Nine months ended September 30, 2026; the company reported no revenue.
Third-quarter net income $642,000 Three months ended September 30, 2026; included gains on settlement and contingent consideration.
Nine-month net loss $2.307 million Nine months ended September 30, 2026, compared with $2.048 million in 2025.
Cash and cash equivalents $1.225 million As of September 30, 2026; management said it was insufficient to fund the following 12 months.
Net cash used in operating activities $2.521 million Nine months ended September 30, 2026, versus $7.408 million in 2025; the company attributed the decrease to reduced spending.
Stockholders’ equity $1.895 million As of September 30, 2026; Nasdaq’s minimum requirement was $2.5 million, with a compliance deadline of December 2, 2026.
GPC-100 asset sale price KRW 6,500,000,000 (approximately $4.810 million) Proposed asset sale to GPCRT under an agreement subject to closing conditions; the parties were negotiating revisions.
NeuroQ development funding Up to $500,000 Exicure intends to provide the funding after closing of the proposed NeuroQ share acquisition.
going concern financial
"substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
material weakness financial
"material weaknesses in the Company’s internal control over financial reporting"
A material weakness is a significant flaw in the systems and checks a company uses to ensure its financial reports are accurate, meaning errors or fraud could happen and not be caught. For investors it matters because it raises the risk that reported results are unreliable—similar to finding a hole in a ship’s hull—potentially leading to corrected financials, regulatory action, reduced trust, and negative effects on stock value and borrowing costs.
contingent consideration financial
"contingent consideration liability associated with the GPCR USA acquisition"
Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.
Level 3 liability financial
"classified as a Level 3 liability under ASC 820"
anti-dilutive financial
"all potentially dilutive shares in such periods were anti-dilutive"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.
discounted cash flow model financial
"probability-weighted discounted cash flow model"
A discounted cash flow model is a valuation method that estimates the present value of a business or asset by forecasting the cash it will generate in the future and then reducing those future amounts to today’s dollars using a discount rate. Think of it like pricing a bond of future paychecks: you predict how much money will come in, then account for risk and time by “discounting” those amounts so you can compare that intrinsic worth to the current market price. It matters to investors because it translates future profits into a single value to help assess whether a stock appears expensive or cheap relative to that estimate.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much cash did XCUR have at September 30, 2026?

Exicure reported $1.225 million in cash and cash equivalents as of September 30, 2026. It reported no revenue for the nine months ended September 30, 2026 and said its cash was insufficient to fund operations for the following 12 months.

What are the terms of XCUR’s GPC-100 asset sale?

Exicure and its subsidiary agreed to sell substantially all GPC-100 program assets to GPCRT for KRW 6,500,000,000, estimated at approximately $4.810 million. Payments include a KRW 500,000,000 deposit already paid, KRW 2,000,000,000 due on or before November 16, 2026, and KRW 4,000,000,000 at closing. The interim payment had not been received as of issuance, and the parties were negotiating revisions.

Why did XCUR report substantial doubt about its ability to continue as a going concern?

Management said the $1.225 million cash balance was insufficient to fund the next 12 months and reported expected negative cash flows and significant future expenses. Exicure said additional financing is needed and that its plans include equity or debt financing and strategic transactions.

What is XCUR’s proposed NeuroQ deal?

The parties intend to pursue Exicure’s acquisition of a 20% to 100% interest in NeuroQ, primarily by exchanging newly issued Exicure shares for shares held by Laonz. After closing, Exicure intends to provide up to $500,000 in development funding. Completion depends on agreement on terms, due diligence and required approvals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
12-31falsefalse0001698530Q3falsefalsefalse20260.02080.02080.02770.0830onehttp://fasb.org/srt/2026#ChiefExecutiveOfficerMember0001698530us-gaap:CommonStockMember2025-07-012025-09-300001698530us-gaap:CommonStockMember2026-07-012026-09-300001698530us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300001698530us-gaap:CommonStockMember2026-04-012026-06-300001698530xcur:NonemployeeDirectorMemberxcur:ExicureInc.2017EquityIncentivePlanMemberxcur:InitialEmployeeStockOptionMember2026-01-012026-09-300001698530us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300001698530us-gaap:ShareBasedCompensationAwardTrancheTwoMemberxcur:InitialEmployeeStockOptionMember2026-01-012026-09-300001698530xcur:ContingentConsiderationMember2024-12-310001698530us-gaap:RetainedEarningsMember2025-07-012025-09-3000016985302025-01-012025-09-300001698530us-gaap:CommonStockMember2025-03-310001698530us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001698530us-gaap:CommonStockMember2026-06-300001698530us-gaap:Liabilities2026-09-300001698530us-gaap:FairValueInputsLevel1Member2026-09-300001698530us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-3000016985302026-07-312026-07-310001698530us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-09-300001698530us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300001698530us-gaap:EmployeeStockOptionMember2026-01-012026-01-010001698530us-gaap:RetainedEarningsMember2026-01-012026-03-310001698530xcur:BiotechnologySegmentMember2025-01-012025-09-300001698530us-gaap:RetainedEarningsMember2025-09-300001698530us-gaap:ShareBasedCompensationAwardTrancheTwoMemberxcur:SubsequentEmployeeStockOptionMember2026-01-012026-09-300001698530us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001698530xcur:BiotechnologySegmentMember2026-01-012026-09-300001698530us-gaap:RetainedEarningsMember2025-04-012025-06-300001698530us-gaap:FairValueInputsLevel3Memberxcur:MilestoneFiveMemberxcur:MeasurementInputProbabilityOfSuccessMember2026-09-300001698530us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300001698530us-gaap:FurnitureAndFixturesMember2026-09-300001698530us-gaap:RetainedEarningsMember2026-07-012026-09-300001698530us-gaap:CommonStockMember2025-06-300001698530us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-09-300001698530srt:MinimumMemberus-gaap:SubsequentEventMemberxcur:NeuroQBiologicsIncMember2026-11-200001698530xcur:LicenseAndCollaborationAgreementMemberxcur:GPCRUSAMember2026-07-310001698530us-gaap:RelatedPartyMember2025-02-012025-02-0100016985302025-04-012025-06-3000016985302026-01-012026-03-3100016985302025-03-310001698530us-gaap:EmployeeStockMember2017-09-300001698530xcur:GPCRUSAMemberxcur:RedwoodCityCaliforniaMember2026-03-030001698530us-gaap:AdditionalPaidInCapitalMember2026-03-310001698530us-gaap:SubsequentEventMembersrt:MaximumMemberxcur:NeuroQBiologicsIncMember2026-11-200001698530xcur:MilestoneSevenMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2026-09-300001698530us-gaap:CommonStockMember2026-03-310001698530xcur:ExicureOpCo2015EquityIncentivePlanMember2017-09-220001698530xcur:ComputersandSoftwareMember2026-09-3000016985302026-07-152026-07-150001698530us-gaap:FairValueInputsLevel3Member2026-09-300001698530us-gaap:CommonStockMember2024-12-310001698530us-gaap:CommonStockMember2025-04-012025-06-300001698530xcur:NonemployeeDirectorMemberxcur:ExicureInc.2017EquityIncentivePlanMemberxcur:SubsequentEmployeeStockOptionMember2026-01-012026-09-300001698530xcur:BiotechnologySegmentMember2026-07-012026-09-300001698530us-gaap:FurnitureAndFixturesMember2025-12-310001698530us-gaap:EquipmentMember2026-09-300001698530us-gaap:EmployeeStockOptionMemberxcur:ExicureInc.2017EquityIncentivePlanMember2026-01-012026-09-3000016985302025-07-012025-09-300001698530us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001698530xcur:ExicureInc.2017EquityIncentivePlanMemberxcur:InitialEmployeeStockOptionMember2026-01-012026-09-300001698530xcur:BiotechnologySegmentMember2025-07-012025-09-300001698530us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001698530us-gaap:AdditionalPaidInCapitalMember2026-06-300001698530us-gaap:RetainedEarningsMember2026-03-310001698530us-gaap:LeaseholdImprovementsMember2025-12-3100016985302024-09-300001698530us-gaap:RetainedEarningsMember2025-06-300001698530xcur:ContingentConsiderationMember2025-12-310001698530us-gaap:AdditionalPaidInCapitalMember2025-03-310001698530us-gaap:EmployeeStockMember2017-09-012017-09-300001698530xcur:ExicureInc.2017EquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberxcur:InitialEmployeeStockOptionMember2026-01-012026-09-3000016985302026-01-012026-09-300001698530us-gaap:CommonStockMember2025-09-300001698530us-gaap:AutomobilesMember2026-09-300001698530us-gaap:CommonStockMember2026-09-300001698530us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001698530us-gaap:EmployeeStockOptionMemberxcur:ExicureInc.2017EquityIncentivePlanMember2026-01-012026-01-010001698530us-gaap:EmployeeStockOptionMember2026-01-012026-09-300001698530xcur:MilestoneSevenMemberus-gaap:FairValueInputsLevel3Memberxcur:MeasurementInputProbabilityOfSuccessMember2026-09-300001698530us-gaap:RelatedPartyMemberxcur:ConsultingAgreementMonthlyPaymentAmountMember2025-02-272025-02-270001698530us-gaap:LeaseholdImprovementsMember2026-09-3000016985302022-03-012022-04-300001698530us-gaap:EmployeeStockOptionMember2026-09-300001698530us-gaap:RetainedEarningsMember2025-12-310001698530xcur:ExicureInc.2017EquityIncentivePlanMember2026-01-012026-09-300001698530us-gaap:EquipmentMember2025-12-3100016985302024-12-310001698530us-gaap:FairValueInputsLevel3Memberxcur:MilestoneThreeMemberxcur:MeasurementInputProbabilityOfSuccessMember2026-09-300001698530xcur:ExicureInc.2017EquityIncentivePlanMember2017-09-220001698530us-gaap:RetainedEarningsMember2026-06-300001698530xcur:GPCRtMemberus-gaap:SubsequentEventMember2026-11-040001698530us-gaap:RetainedEarningsMember2024-12-310001698530xcur:ContingentConsiderationMember2025-01-012025-12-3100016985302026-04-012026-06-3000016985302025-01-012025-03-310001698530us-gaap:RetainedEarningsMember2026-04-012026-06-300001698530us-gaap:CommonStockMember2026-07-312026-07-310001698530us-gaap:RetainedEarningsMember2026-09-300001698530us-gaap:AutomobilesMember2025-12-310001698530us-gaap:CommonStockMember2026-07-310001698530xcur:ExicureInc.2017EquityIncentivePlanMember2026-09-300001698530us-gaap:RetainedEarningsMember2025-03-310001698530us-gaap:FairValueInputsLevel3Memberxcur:MilestoneSixMemberxcur:MeasurementInputProbabilityOfSuccessMember2026-09-300001698530us-gaap:CommonStockMember2025-12-310001698530us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001698530us-gaap:FairValueInputsLevel3Memberxcur:MilestoneTwoMemberxcur:MeasurementInputProbabilityOfSuccessMember2026-09-3000016985302026-11-180001698530us-gaap:EmployeeStockOptionMember2017-09-300001698530xcur:MilestoneOneMember2026-07-3100016985302025-07-290001698530xcur:GPCRUSAMemberxcur:RedwoodCityCaliforniaMember2026-03-090001698530us-gaap:AdditionalPaidInCapitalMember2025-06-3000016985302025-09-300001698530xcur:ContingentConsiderationMember2026-09-300001698530us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberxcur:MilestoneTwoMember2026-09-300001698530xcur:NonemployeeDirectorMemberxcur:ExicureOpCo2015EquityIncentivePlanMemberxcur:InitialEmployeeStockOptionMember2026-01-012026-09-3000016985302026-06-300001698530xcur:ChicagoMember2025-01-012025-03-310001698530us-gaap:AdditionalPaidInCapitalMember2025-09-3000016985302026-09-300001698530us-gaap:EmployeeStockOptionMember2017-09-012017-09-300001698530xcur:ContingentConsiderationMember2026-01-012026-09-300001698530us-gaap:RelatedPartyMemberxcur:ConsultingAgreementAmountPaidMember2025-02-272025-02-270001698530xcur:GPCRUSAMemberxcur:RedwoodCityCaliforniaMember2022-07-150001698530xcur:GPCRtMemberus-gaap:SubsequentEventMember2026-10-282026-10-280001698530us-gaap:FairValueInputsLevel3Memberxcur:MilestoneFourMemberus-gaap:MeasurementInputDiscountRateMember2026-09-300001698530us-gaap:FairValueInputsLevel3Memberxcur:MilestoneThreeMemberus-gaap:MeasurementInputDiscountRateMember2026-09-300001698530us-gaap:RetainedEarningsMember2025-01-012025-03-310001698530us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001698530us-gaap:AdditionalPaidInCapitalMember2026-09-3000016985302026-07-012026-09-300001698530us-gaap:EmployeeStockMembersrt:ScenarioForecastMember2026-01-012026-12-310001698530us-gaap:AdditionalPaidInCapitalMember2025-12-310001698530us-gaap:WarrantMember2025-01-012025-09-300001698530xcur:NonemployeeDirectorMemberxcur:ExicureOpCo2015EquityIncentivePlanMemberxcur:SubsequentEmployeeStockOptionMember2026-01-012026-09-300001698530us-gaap:CommonStockMember2025-01-012025-03-310001698530xcur:LicenseAndCollaborationAgreementMemberxcur:GPCRUSAMember2026-07-312026-07-310001698530us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001698530xcur:ColwellV.ExicureMemberus-gaap:SettledLitigationMember2025-01-132025-01-1300016985302026-03-310001698530xcur:GPCRUSAMemberxcur:RedwoodCityCaliforniaMember2022-07-152022-07-150001698530us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberxcur:MilestoneFiveMember2026-09-300001698530us-gaap:FairValueInputsLevel3Memberxcur:MilestoneSixMemberus-gaap:MeasurementInputDiscountRateMember2026-09-300001698530us-gaap:FairValueInputsLevel3Memberxcur:MilestoneOneMemberxcur:MeasurementInputProbabilityOfSuccessMember2026-09-3000016985302025-06-300001698530us-gaap:FairValueInputsLevel2Member2026-09-300001698530us-gaap:FairValueInputsLevel3Memberxcur:MilestoneFourMemberxcur:MeasurementInputProbabilityOfSuccessMember2026-09-300001698530us-gaap:AdditionalPaidInCapitalMember2024-12-310001698530us-gaap:EmployeeStockMember2025-01-012025-12-310001698530xcur:ComputersandSoftwareMember2025-12-310001698530us-gaap:EmployeeStockOptionMember2025-12-310001698530us-gaap:WarrantMember2026-01-012026-09-300001698530us-gaap:AccruedLiabilitiesCurrent2025-12-3100016985302025-12-310001698530xcur:ExicureInc.2017EquityIncentivePlanMemberxcur:SubsequentEmployeeStockOptionMember2026-01-012026-09-300001698530us-gaap:CommonStockMember2026-01-012026-03-31xbrli:pureiso4217:KRWutr:sqftiso4217:USDxbrli:sharesxbrli:sharesxcur:Lawsuitxcur:Segmentiso4217:USDxcur:Vote

Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

or

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39011

 

 

EXICURE, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

81-5333008

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

103 Foulk Road , Suite 202

Wilmington, DE 19803

(Address of principal executive offices)

Registrant’s telephone number, including area code (847) 673-1700

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

XCUR

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

 

Accelerated filer

☐

Non-accelerated filer

☒

 

Smaller reporting company

☒

 

 

 

Emerging growth company

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 18, 2026, there were 6,545,995 shares of the registrant’s common stock, par value $0.0001 per share (“Common Stock”), outstanding.

 


Table of Contents

 

 

PART I - FINANCIAL INFORMATION

6

Item 1. Financial Statements

 

Unaudited Condensed Consolidated Balance Sheets

6

Unaudited Condensed Consolidated Statements of Operations

7

Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss)

8

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity

9

Unaudited Condensed Consolidated Statements of Cash Flows

11

Notes to Unaudited Condensed Consolidated Financial Statements

12

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

25

Item 3. Quantitative and Qualitative Disclosures About Market Risk

34

Item 4. Controls and Procedures

34

 

 

PART II - OTHER INFORMATION

36

Item 1. Legal Proceedings

36

Item 1A. Risk Factors

38

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

38

Item 6. Exhibits

38

 

 

Signatures

39

 

 


Table of Contents

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains express or implied “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact contained in this Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “project,” “continue,” “potential,” “ongoing” or the negative forms of these terms or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements.

Our expectations involve risks and uncertainties, including the factors described below and elsewhere in this Quarterly Report on Form 10-Q. Actual results could differ materially from those expressed or implied by our forward looking statements.

Forward-looking statements included in this Quarterly Report on Form 10-Q are subject to inherent risks and uncertainties, including, but not limited to, factors concerning the following:

•
substantial uncertainties regarding our exploration of strategic alternatives to maximize stockholder value, including whether we are able to complete the proposed disposition of the GPC-100 program, obtain any required approvals and identify other strategic opportunities, in a timely manner or at all, whether we would be able to obtain sufficient funding to complete this process and whether any such transactions would generate value for stockholders;
•
our ability to raise the additional capital that is needed to fund our operations and our pursuit of strategic alternatives, particularly given our current lack of a revenue source and the substantial doubt about our ability to continue as a going concern;
•
our ability to remain listed on The Nasdaq Capital Market (“Nasdaq”), including the ability to comply with the minimum stockholders’ equity requirement and maintain stock price, and comply with applicable governance requirements, for continued listing on Nasdaq;
•
any strategic plan or alternative that we may identify and pursue may involve unexpected costs, liabilities and/or delays and may not deliver anticipated benefits to our stockholders;
•
our estimates of expenses, use of cash, timing of future cash needs, ongoing losses and capital requirements may prove to be inaccurate;
•
uncertainty about reaction from investors and potential business partners to our recent changes of control and board of directors (the “Board”) and management composition and the future direction of the Company, and the ability of our controlling stockholders and new Board members and management to earn the confidence of investors and potential partners despite limited experience with U.S. public companies, and how these factors may impact our ability to obtain funding and execute any strategic alternatives that we may identify;
•
potential turnover of senior management in the near term, and any inability to attract and retain qualified management and other key personnel, could create significant continuity risk and could impair our ability to raise capital and execute on our exploration of strategic alternatives;
•
our ability to comply with all applicable laws, which may be particularly challenging given the recent turnover in our Board and management, significant reductions in force, limited resources and the potential to enter into new business areas with which we have no past experience;
•
the ability of investors to assess our operations, which are primarily within subsidiaries whose performance are stated on the Company’s financial statements on a condensed consolidated basis;
•
our ability to obtain and maintain intellectual property protection for our technologies and our ability to operate our business without infringing the intellectual property rights of others;
•
the impact of macroeconomic conditions, including global inflation, actions taken by central banks to counter inflation, capital market and bank instability, exchange rate fluctuations, supply chain disruptions and energy and fuel prices and uncertainty and disruption caused by geopolitical events, including the conflicts in Ukraine, Russia, and the Middle East;

 


Table of Contents

 

•
the impact of government laws and regulations, including but not limited to taxes and tariffs; and
•
risk factors set forth in Part I, Item 1A “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented by Part II, Item 1A, 'Risk Factors,' of this Quarterly Report on Form 10-Q, and other factors that may impact our financial results and condition and our ongoing strategic efforts.

Forward-looking statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.

Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed with the SEC as exhibits thereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no, and specifically decline any, obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Except where the context otherwise requires, in this Quarterly Report on Form 10-Q, the terms the “Company,” “Exicure,” “we,” “us” and “our” refer to Exicure, Inc., a Delaware corporation, and, where appropriate, our subsidiaries.

 


Table of Contents

 

PART I - FINANCIAL INFORMATION

EXICURE, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

 

September 30,
2026

 

 

December 31,
2025

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

1,225

 

 

$

3,746

 

Other receivable

 

 

2

 

 

 

58

 

Prepaid expenses and other current assets

 

 

545

 

 

 

820

 

Total current assets

 

 

1,772

 

 

 

4,624

 

Other noncurrent assets

 

 

612

 

 

 

928

 

Property and equipment, net

 

 

140

 

 

 

306

 

Goodwill

 

 

4,399

 

 

 

4,399

 

Intangible asset

 

 

3,784

 

 

 

3,784

 

Total assets

 

$

10,707

 

 

$

14,041

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,000

 

 

$

1,690

 

Accrued expenses and other current liabilities

 

 

1,038

 

 

 

2,198

 

Total current liabilities

 

 

3,038

 

 

 

3,888

 

Contingent consideration

 

 

5,351

 

 

 

5,804

 

Deferred tax liability

 

 

423

 

 

 

423

 

Total liabilities

 

 

8,812

 

 

 

10,115

 

 

 

 

 

 

 

 

Commitments and Contingencies (Note 11)

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no
   shares issued and outstanding, September 30, 2026 and December 31, 2025

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value per share; 200,000,000 shares
   authorized,
6,545,995 issued and outstanding, September 30, 2026
   ;
6,373,893 issued and outstanding, December 31, 2025

 

 

1

 

 

 

1

 

Additional paid-in capital

 

 

208,413

 

 

 

208,137

 

Accumulated other comprehensive loss

 

 

(2

)

 

 

(2

)

Accumulated deficit

 

 

(206,517

)

 

 

(204,210

)

Total stockholders’ equity

 

 

1,895

 

 

 

3,926

 

Total liabilities and stockholders’ equity

 

$

10,707

 

 

$

14,041

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

6


Table of Contents

 

EXICURE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Total revenue

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expense

 

 

146

 

 

 

888

 

 

 

632

 

 

 

2,631

 

General and administrative expense

 

 

624

 

 

 

1,499

 

 

 

2,804

 

 

 

5,230

 

Loss on disposal of assets

 

 

—

 

 

 

4

 

 

 

28

 

 

 

90

 

Gain on early lease termination

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(5,974

)

Total operating expenses

 

 

770

 

 

 

2,391

 

 

 

3,464

 

 

 

1,977

 

Operating loss

 

 

(770

)

 

 

(2,391

)

 

 

(3,464

)

 

 

(1,977

)

Other (expense) income, net:

 

 

 

 

 

 

 

 

 

 

 

 

Dividend income

 

 

1

 

 

 

27

 

 

 

1

 

 

 

106

 

Interest income

 

 

—

 

 

 

29

 

 

 

11

 

 

 

38

 

Gain on settlement of accounts payable

 

 

724

 

 

 

155

 

 

 

724

 

 

 

346

 

Change in fair value of contingent consideration liability

 

 

688

 

 

 

(246

)

 

 

448

 

 

 

(541

)

Other expense, net

 

 

(1

)

 

 

(11

)

 

 

(27

)

 

 

(20

)

Total other income (expense), net

 

 

1,412

 

 

 

(46

)

 

 

1,157

 

 

 

(71

)

Net (loss) income before provision for income taxes

 

 

642

 

 

 

(2,437

)

 

 

(2,307

)

 

 

(2,048

)

Provision for income taxes

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Net (loss) income

 

$

642

 

 

$

(2,437

)

 

$

(2,307

)

 

$

(2,048

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income per common share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.10

 

 

$

(0.39

)

 

$

(0.36

)

 

$

(0.33

)

Diluted

 

$

0.10

 

 

$

(0.39

)

 

$

(0.36

)

 

$

(0.33

)

Weighted-average common shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

6,482,408

 

 

 

6,322,078

 

 

 

6,410,477

 

 

 

6,271,229

 

Diluted

 

 

6,482,441

 

 

 

6,322,078

 

 

 

6,410,477

 

 

 

6,271,229

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

 

7


Table of Contents

 

EXICURE, INC.

 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Net (loss) income

 

$

642

 

 

$

(2,437

)

 

$

(2,307

)

 

$

(2,048

)

Other comprehensive income, net of taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

 

—

 

 

 

1

 

 

 

—

 

 

 

102

 

Other comprehensive income

 

 

—

 

 

 

1

 

 

 

—

 

 

 

102

 

Comprehensive (loss) income

 

$

642

 

 

$

(2,436

)

 

$

(2,307

)

 

$

(1,946

)

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

8


Table of Contents

 

EXICURE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands, except shares)

 

 

Common Stock

 

 

Additional
Paid-in-

 

 

Accumulated Other
Comprehensive

 

 

Accumulated

 

 

Total
Stockholders'

 

 

Shares

 

 

$

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balance at January 1, 2026

 

 

6,373,893

 

 

$

1

 

 

$

208,137

 

 

$

(2

)

 

$

(204,210

)

 

$

3,926

 

Vesting of restricted stock units

 

 

22

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(1,828

)

 

 

(1,828

)

Balance at March 31, 2026

 

 

6,373,915

 

 

$

1

 

 

$

208,137

 

 

$

(2

)

 

$

(206,038

)

 

$

2,098

 

Vesting of restricted stock units

 

 

22

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(1,121

)

 

 

(1,121

)

Balance at June 30, 2026

 

 

6,373,937

 

 

$

1

 

 

$

208,137

 

 

$

(2

)

 

$

(207,159

)

 

$

977

 

Issuance of common stock

 

 

172,058

 

 

 

—

 

 

 

276

 

 

 

—

 

 

 

—

 

 

 

276

 

Net income

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

642

 

 

 

642

 

Balance at September 30, 2026

 

 

6,545,995

 

 

 

1

 

 

 

208,413

 

 

 

(2

)

 

 

(206,517

)

 

 

1,895

 

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9


Table of Contents

 

EXICURE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands, except shares)

 

 

Common Stock

 

 

Additional
Paid-in-

 

 

Accumulated

 

 

Accumulated Other Comprehensive

 

 

Total
Stockholders'

 

 

Shares

 

 

$

 

 

Capital

 

 

Deficit

 

 

Loss

 

 

Equity

 

Balance at January 1, 2025

 

 

6,026,841

 

 

$

1

 

 

$

206,035

 

 

$

(199,264

)

 

$

—

 

 

$

6,772

 

Vesting of restricted stock units

 

 

22

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock, net

 

 

290,908

 

 

 

—

 

 

 

1,600

 

 

 

—

 

 

 

—

 

 

 

1,600

 

Net income

 

 

—

 

 

 

—

 

 

 

—

 

 

 

3,010

 

 

 

—

 

 

 

3,010

 

Balance at March 31, 2025

 

 

6,317,771

 

 

$

1

 

 

$

207,635

 

 

$

(196,254

)

 

$

—

 

 

$

11,382

 

Equity-based compensation

 

 

—

 

 

 

—

 

 

 

1

 

 

 

—

 

 

 

—

 

 

 

1

 

Vesting of restricted stock units and related purchases

 

 

22

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Foreign currency translation adjustment

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

101

 

 

 

101

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(2,621

)

 

 

—

 

 

 

(2,621

)

Balance at June 30, 2025

 

 

6,317,793

 

 

$

1

 

 

$

207,636

 

 

$

(198,875

)

 

$

101

 

 

$

8,863

 

Vesting of restricted stock units

 

 

23

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock

 

 

56,053

 

 

 

—

 

 

 

500

 

 

 

—

 

 

 

—

 

 

 

500

 

Foreign currency translation adjustment

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1

 

 

 

1

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(2,437

)

 

 

—

 

 

 

(2,437

)

Balance at September 30, 2025

 

 

6,373,869

 

 

$

1

 

 

$

208,136

 

 

$

(201,312

)

 

$

102

 

 

$

6,927

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

10


Table of Contents

 

EXICURE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

 

Nine Months Ended September 30,

 

 

2026

 

 

2025

 

Cash flows from operating activities:

 

 

 

 

 

 

Net income (loss)

 

$

(2,307

)

 

$

(2,048

)

Adjustments to reconcile net loss to cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

127

 

 

 

214

 

Equity-based compensation

 

 

—

 

 

 

1

 

Amortization of right-of-use asset

 

 

57

 

 

 

89

 

Change in fair value of contingent consideration

 

 

(448

)

 

 

541

 

Gain on early lease termination

 

 

—

 

 

 

(5,974

)

Gain on settlement of accounts payable

 

 

(724

)

 

 

(346

)

Loss from sale or disposal of property and equipment

 

 

28

 

 

 

90

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Other receivable

 

 

56

 

 

 

1,457

 

Prepaid expenses and other current assets

 

 

529

 

 

 

42

 

Other noncurrent assets

 

 

—

 

 

 

(655

)

Accounts payable

 

 

310

 

 

 

(227

)

Accrued expenses

 

 

(149

)

 

 

(592

)

Net cash used in operating activities

 

 

(2,521

)

 

 

(7,408

)

Cash flows from investing activities:

 

 

 

 

 

 

Property and equipment

 

 

—

 

 

 

(214

)

Proceeds from sale of fixed assets

 

 

—

 

 

42

 

Acquisition of GPCR Therapeutics USA Inc.

 

 

—

 

 

 

(2,090

)

Net cash used in investing activities

 

 

—

 

 

 

(2,262

)

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from common stock offering

 

 

—

 

 

 

1,600

 

Net cash provided by financing activities

 

 

—

 

 

 

1,600

 

 

 

 

 

 

 

 

Net decrease in cash and cash equivalents

 

 

(2,521

)

 

 

(8,070

)

Cash and cash equivalents - beginning of period

 

 

3,746

 

 

 

12,508

 

Cash and cash equivalents - end of period

 

$

1,225

 

 

$

4,438

 

 

 

Nine Months Ended September 30,

 

 

2026

 

 

2025

 

Supplemental disclosure of cash flow information

 

 

 

 

 

 

Non-cash operating activities:

 

 

 

 

 

 

Reclass of legal expenses from accruals to accounts payable

 

$

—

 

 

$

190

 

Issuance of stock to GPCR Korea

 

$

276

 

 

$

500

 

Non-cash investing activities:

 

 

 

 

 

 

Reclass prepaid expenses from noncurrent to current

 

$

316

 

 

$

321

 

Initial recording of ROU asset and related lease liability

 

$

—

 

 

$

100

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

11


Table of Contents

 

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

1. Description of Business, Basis of Presentation and Going Concern

Description of Business

Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following the change in the Company's ownership, board composition and management team, the Company is evaluating a range of strategic alternatives intended to maximize stockholder value, including potential acquisitions, financings, strategic partnerships and other business combination opportunities.

On January 19, 2025, the Company entered into a share purchase agreement (the “Share Purchase Agreement”) with GPCR Therapeutics Inc., a Korean corporation, (“GPCR”), pursuant to which the Company acquired from GPCR all of the issued and outstanding equity securities of its then-subsidiary, GPCR Therapeutics USA Inc., a California corporation (“GPCR USA”). In connection with the closing of the transaction pursuant to the Share Purchase Agreement, the Company and GPCR entered into a License and Collaboration Agreement to further develop and commercialize GPCR’s technologies related to certain intellectual property and patents (the “License and Collaboration Agreement”). The License and Collaboration Agreement requires the Company to make milestone payments to GPCR upon the achievement of specific milestone events relating to clinical trials, marketing authorizations, and net sales, as well as for the Company to pay recurring royalty payments, as set forth in the agreement.

GPCR USA completed its Phase 2 clinical trial in January 2026. The trial evaluated the combined administration of GPC-100 and propranolol for stem-cell mobilization in patients with multiple myeloma. The related $1,000 milestone obligation under the License and Collaboration Agreement was settled on July 31, 2026 through the issuance of 172,058 shares of the Company’s common stock.

The Company formed KC Creation Co., Ltd. ("KC Creation") as a wholly owned South Korean subsidiary on March 26, 2025 and sold it on November 24, 2025.

On February 24, 2026, the Company incorporated a wholly-owned subsidiary, Exicure Canada Incorporated, under the laws of British Columbia, Canada.

The Company and GPCRT Inc. (“GPCRT”) entered into a memorandum of understanding dated August 25, 2026 concerning a possible sale of specified GPC-100 program assets. On November 4, 2026, the Company and GPCR USA entered into a definitive asset sale agreement with GPCRT (Note 13). Closing is subject to conditions, including any required stockholder approval.

In these condensed consolidated financial statements, “Company,” and “Exicure” refer to Exicure, Inc. and where appropriate, its consolidated subsidiaries.

12


Table of Contents

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements as of September 30, 2026 and December 31, 2025, and for the three and nine months ended September 30, 2026 and 2025, have been presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Exchange Act.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiaries, Exicure Operating Company, GPCR USA, and Exicure Canada Incorporated. All intercompany transactions and accounts are eliminated in consolidation.

Unaudited Interim Financial Information

The condensed consolidated financial statements provided herewith are unaudited. Such statements include interim condensed consolidated balance sheet as of September 30, 2026, the interim condensed consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2026 and 2025, the interim condensed consolidated statements of changes in stockholders’ equity for the three and nine months ended September 30, 2026 and 2025, and the interim condensed consolidated statements of cash flows for the nine months ended September 30, 2026 and 2025. In the opinion of management, the interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Exchange Act; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of September 30, 2026, the results of its operations for the three and nine months ended September 30, 2026 and 2025, and the results of its cash flows for the nine months ended September 30, 2026 and 2025. The financial data and other information disclosed in these notes related to the nine months ended September 30, 2026 and 2025 are unaudited. The results for the nine months ended September 30, 2026 are not necessarily indicative of results to be expected for the year ending December 31, 2026, or any other interim periods, or any future year or period. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2025, included in the Company’s corresponding Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 25, 2026 (the “Annual Report”).

Going Concern

At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that the condensed consolidated financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists that is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern.

The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern for a period of one year after the date that the condensed consolidated financial statements are issued. As of September 30, 2026, the Company expects to incur significant expenses and negative cash flows for the foreseeable future. As of September 30, 2026, the Company’s cash and cash equivalents were $1,225. Management believes that the Company’s existing cash and cash equivalents will not be sufficient to fund planned operations for at least

13


Table of Contents

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

the twelve-month period following issuance of these financial statements. There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms.

Management believes that, given the Company’s current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. Additional financing will be needed to fund ongoing operations, support of GPCR USA’s operations, and exploration of strategic alternatives and pursuing any alternatives that management identifies. Management's plans to address this substantial doubt include pursuing additional equity and/or debt financings, strategic transactions, potential business combination opportunities and other sources of capital. However, there can be no assurance that such plans will be successful.

The accompanying unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Reclassification

Certain accounts in the prior period condensed consolidated financial statements have been reclassified to conform to the presentation of the current year condensed consolidated financial statements. These reclassifications had no effect on the previously reported operating results.

2. Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the Annual Report on Form 10-K (the “Annual Report”) for the year ended December 31, 2025 filed with the SEC on March 25, 2026.

 

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among others, the valuation of the contingent consideration, the assessment of goodwill and identifiable intangible assets, going concern considerations and accrued liabilities. Actual results could differ materially from those estimates.

 

Recent Accounting Pronouncements

14


Table of Contents

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

Disaggregation of Income Statement Expenses

In November 2024, the Financial Accounting Standards Board (“FASB”) issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income -Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” The standard requires that public business entities disclose additional information about specific expense categories in the notes to financial statements for interim and annual reporting periods. The standard will become effective for the Company for the fiscal year 2027 annual financial statements and interim financial statements thereafter and may be applied prospectively to periods after the adoption date or retrospectively for all prior periods presented in the financial statements, with early adoption permitted. The Company plans to adopt the standard when it becomes effective in the fiscal year 2027 annual financial statements, and the Company is currently evaluating the impact this guidance will have on the disclosures included in the Notes to the Consolidated Financial Statements.

Interim Reporting—Narrow-Scope Improvements

In December 2025, the FASB issued ASU 2025-11, “Interim Reporting (Topic 270): Narrow-Scope Improvements”. The amendments clarify when Topic 270 applies, the form and content of interim financial statements, and which disclosures are required in interim periods. They are not intended to change the fundamental nature of interim reporting or to expand existing interim disclosure requirements. The Company plans to adopt the standard when it becomes effective for interim periods beginning in fiscal year 2028, and the Company is currently evaluating the impact this guidance will have on the disclosures included in the Notes to the Consolidated Financial Statements.

Codification Improvements

In December 2025, the FASB issued ASU 2025-12, “Codification Improvements”, which includes various clarifications, technical corrections, and enhancements to several areas of the FASB Accounting Standards Codification. The amendments are intended to improve the consistency, usability, and application of existing guidance and do not introduce new accounting models. Key areas addressed by the ASU include clarifications related to diluted earnings per share, lease receivables for sales-type and direct financing leases, and the calculation of reference amounts for certain beneficial interests. The Company adopted ASU 2025-12 on January 1, 2026. Adoption of the standard did not have a material impact on the Company’s condensed consolidated financial statements or related disclosures.

 

3. Supplemental Balance Sheet Information

Prepaid expenses and other current assets

 

 

September 30, 2026

 

 

December 31, 2025

 

Prepaid insurance

 

$

468

 

 

$

438

 

Prepaid professional fees

 

 

—

 

 

 

20

 

Prepaid software

 

 

27

 

 

 

78

 

Right of use asset

 

 

—

 

 

 

67

 

Lease security deposit

 

 

—

 

 

 

188

 

Other

 

 

50

 

 

 

29

 

Prepaid expenses and other current assets

 

$

545

 

 

$

820

 

 

15


Table of Contents

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

Property and equipment, net

 

 

September 30, 2026

 

 

December 31, 2025

 

Scientific equipment

 

$

357

 

 

$

405

 

Computers and software

 

 

5

 

 

 

5

 

Furniture and fixtures

 

 

2

 

 

 

25

 

Leasehold Improvements

 

 

39

 

 

 

39

 

Auto

 

 

27

 

 

 

27

 

Property and equipment, gross

 

 

430

 

 

 

501

 

Less: accumulated depreciation and amortization

 

 

(290

)

 

 

(195

)

Property and equipment, net

 

$

140

 

 

$

306

 

 

Depreciation and amortization expense was $127 and $214 for the nine months ended September 30, 2026 and 2025, respectively. During the period ended September 30, 2026, the Company wrote off $38 of property and equipment and recognized a loss of $28 in the accompanying statement of operations.

Other noncurrent assets

 

 

September 30, 2026

 

 

December 31, 2025

 

Prepaid insurance

 

$

607

 

 

$

928

 

Security deposit

 

 

5

 

 

 

—

 

Other noncurrent assets

 

$

612

 

 

$

928

 

 

The prepaid insurance balance relates primarily to directors’ and officers’ liability insurance and other insurance policies with coverage periods extending beyond twelve months from the applicable balance sheet date.

Accrued expenses and other current liabilities

 

 

September 30, 2026

 

 

December 31, 2025

 

Current lease liability

 

$

—

 

 

$

176

 

Accrued payroll-related expenses

 

 

89

 

 

 

82

 

Accrued litigation and legal fees

 

 

250

 

 

 

250

 

Accrued registration delay payments

 

 

322

 

 

 

396

 

Accrued contingent consideration, current portion

 

 

—

 

 

 

995

 

Accrued other expenses

 

 

6

 

 

 

299

 

Deposit received from GPCRT

 

 

371

 

 

 

—

 

Accrued expenses and other current liabilities

 

$

1,038

 

 

$

2,198

 

 

 

4. Leases

Redwood City Lease

Prior to its termination in April 2026, the Company’s lease arrangements consisted of a sublease for office space at its headquarters in Redwood City, California that commenced in July 2022 (the “Redwood Sublease”). The Redwood Sublease was classified as an operating lease, and as of September 30, 2026, it is no longer active.

GPCR USA was subleasing approximately 8,392 square feet of office space in Redwood City, California for its operations that began on July 15, 2022. This 45-month sublease is an operating lease agreement that ended on April 14, 2026. The monthly base rent was approximately $50 for the first six months after the Acquisition. Base rent thereafter is subject to

16


Table of Contents

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

an increase of 3% over the remaining nine months. On January 29, 2026, the Company received a payment demand letter and notice of default from Dren Bio Management, Inc. (formerly known as Dren Brio, Inc.) (“Dren Bio”) whereby Dren Bio notified the Company that an event of default has occurred under the sublease for failure to make rent payments and related late charges and interest and demanded that the Company immediately pay the past due rent and late charges and interest. On March 3, 2026, the Company received a Three Day Notice to Pay Rent or Quit from Dren Bio demanding payment of unpaid rent payments of approximately $0.7 million in connection with the sublease of its facilities situated in Redwood City or in the alternative quit and deliver up possession of the premises. Following receipt of such notice, the Company did not remit a payment and on March 9, 2026, Dren Bio filed a Complaint for Unlawful Detainer against GPCR USA in the Superior Court of California, County of San Mateo, seeking restitution of possession of the premises and forfeiture of the sublease and the unpaid rent payments of approximately $0.7 million, damages and attorney’s fees. The Company vacated the facility in Redwood City as of April 15, 2026. The Company is currently reviewing the complaint and evaluating its available defenses and potential responses.

Chicago Lease

On February 13, 2025, the Company executed a Lease Termination Agreement with its landlord related to the Chicago, Illinois lease effective as of January 31, 2025 (the “Chicago Lease”). As a result of this early termination for the Chicago Lease that commenced on July 1, 2020 and would have ended on June 30, 2030, the Company vacated the Chicago office and stopped paying any further amounts owed to its landlord. There were no additional fees or costs related to the early termination. The Company recognized a $5,974 gain in the first quarter of 2025 related to this early termination. The gain was recognized upon the extinguishments of substantially all remaining obligations under the Chicago Lease and is not expected to recur in future periods.

5. Stockholders’ Equity

Preferred Stock

The Company has 10,000,000 shares of preferred stock, par value $0.0001 authorized and no shares issued and outstanding.

Common Stock

The Company has authorized 200,000,000 shares of common stock, par value $0.0001. As of September 30, 2026 and December 31, 2025, the Company had 6,545,995 and 6,373,893 shares issued and outstanding, respectively. On July 31, 2026, the Company issued 172,058 shares of common stock to settle the $1,000 Phase 2 milestone obligation to GPCR. The shares were measured at their issuance-date fair value of approximately $276, based on $1.60 per share. The Company derecognized the $1,000 liability and recognized a gain on settlement of accounts payable of approximately $724, which is included in statements of operations. The issuance was a noncash transaction.

 

The holders of Common Stock are entitled to one vote per share on all matters to be voted upon by the Company’s stockholders, and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of Common Stock are entitled to receive ratably any dividends that may be declared from time to time by the Board out of funds legally available for that purpose. In the event of the Company’s liquidation, dissolution or winding up, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to

17


Table of Contents

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

prior distribution rights of preferred stock then outstanding. Common Stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to Common Stock. The outstanding shares of Common Stock are fully paid and non-assessable.

Common Stock Warrants

As of September 30, 2026 and December 31, 2025, warrants to purchase 10,022 shares of common stock at a price of $40.5155 per share that were acquired in the December 2021 registered-direct offering transaction remain outstanding.

6. Equity-Based Compensation

2017 Equity Incentive Plan

On September 22, 2017, the Company’s stockholders approved the Exicure, Inc. 2017 Equity Incentive Plan (the “2017 Plan”), which became effective on November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to 38,950 shares of Exicure common stock, which includes 14,466 shares of Exicure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed 25,559 that are subject to issued and outstanding awards under the Exicure OpCo 2015 Equity Incentive Plan (the “2015 Plan”) and were assumed in the merger transaction on September 26, 2017. Awards that may be awarded under the 2017 Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 30,667 shares, (ii) 5% of the total number of shares of its capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board (the “Compensation Committee”). No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan. On January 1, 2026, pursuant to the terms of the 2017 Plan, the number of awards that are reserved and may be awarded under the 2017 Plan was automatically increased by 30,667 awards. As of September 30, 2026, the aggregate number of awards available for grant under the 2017 Plan was 154,672.

Awards granted under the 2017 Plan are contingent on the participants’ continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason. The initial award granted to an employee or consultant generally vests 25% on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of 48 months. Subsequent awards granted to employees or consultants generally vest 1/48th monthly until fully vested at the end of 48 months. The initial stock option grant to a non-employee director vests 1/36th monthly until fully vested at the end of 36 months. Subsequent stock option grants to a non-employee director vests 1/12th monthly until fully vested at the end of 12 months. The term of common stock option grants is 10 years unless terminated earlier as described above.

Equity-based compensation expense for the three and nine months ended September 30, 2026 and for the year ended December 31, 2025 is included in the condensed consolidated financial statements and is immaterial.

Employee Stock Purchase Plan

The 2017 Employee Stock Purchase Plan (the “ESPP”) was adopted by the Board in September 2017 and approved by the Company’s stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to 15% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase

18


Table of Contents

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

on any exercise date in an offer period will be the smaller of (i) 50 shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to $25,000 within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to 85% of the lower of (i) the closing market price per share of Exicure common stock on the employee’s offering date or (ii) the closing market price per share of Exicure common stock on the exercise date. Each offering period is approximately six months in duration and the first offering period began on November 16, 2020 and ended on May 14, 2021. No shares were issued during 2026 or 2025.

The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) 2,000 shares; (ii) 0.3% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. As of December 31, 2025, there were 12,394 shares available for issuance under the ESPP. On January 1, 2026, the number of shares of common stock available for issuance under the ESPP increased by 10,000 shares. As of September 30, 2026, there were 22,394 shares available for issuance under the ESPP.

7. Segment Reporting

The Company manages its business activities on a consolidated basis and operates as a single operating segment: Biotechnology. The accounting policies of the Biotechnology segment are the same as those described in Note 2 – Significant Accounting Policies.

The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer, Jung Soo Kim. The CODM uses net (loss) income, as reported on its condensed consolidated Statements of operations, in evaluating Biotechnology segment and determining how to allocate resources of the Company as a whole. Company’s activities during the periods presented primarily consisted of supporting GPCR USA’s clinical development activities, maintaining public company operations and evaluating strategic alternatives. The Company did not generate revenue during the three and nine months ended September 30, 2026 or the comparable periods in 2025.

The following table provides the operating financial results of the Biotechnology segment:

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2026

 

 

2025

 

2026

 

 

2025

 

Total revenues

 

$

—

 

 

$

—

 

$

—

 

 

$

—

 

Significant segment expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development expense

 

 

146

 

 

 

888

 

 

632

 

 

 

2,631

 

General and administrative expense

 

 

624

 

 

 

1,499

 

 

2,804

 

 

 

5,230

 

Loss on disposal of assets

 

 

—

 

 

 

4

 

 

28

 

 

 

90

 

Gain on lease termination

 

 

—

 

 

 

—

 

 

—

 

 

 

(5,974

)

Total operating expenses

 

 

(770

)

 

 

(2,391

)

 

(3,464

)

 

 

(1,977

)

Interest and dividend income

 

 

1

 

 

 

56

 

 

12

 

 

 

144

 

Gain on settlement of accounts payable

 

 

724

 

 

 

155

 

 

724

 

 

 

346

 

Change in fair value of contingent consideration liability

 

 

688

 

 

 

(246

)

 

448

 

 

 

(541

)

Other income (expense)

 

 

(1

)

 

 

(11

)

 

(27

)

 

 

(20

)

Total other income

 

 

1,412

 

 

 

(46

)

 

1,157

 

 

 

(71

)

Segment net (loss) income

 

$

642

 

 

$

(2,437

)

$

(2,307

)

 

$

(2,048

)

 

19


Table of Contents

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

 

8. Income Taxes

The Company incurred pretax income in the three months ended September 30, 2026, but does not expect to end the fiscal year with pretax income. The Company incurred pretax loss for the three months ended September 30, 2025, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended. The effective tax rate is 0% in each of the nine months ended September 30, 2026 and 2025 because the Company will and has generated tax losses and has provided a full valuation allowance against its deferred tax assets.

9. (Loss) Income Per Common Share

Basic net (loss) income per common share is calculated by dividing net (loss) income by the weighted-average number of shares of common stock outstanding during the period. Diluted net (loss) income per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive restricted stock units that were outstanding for the three months ended September 30, 2026, were included in the diluted income per share calculation. Options and warrants to purchase common stock were excluded because their effect was anti-dilutive. As a result of the net loss for the nine months ended September 30, 2026 and the three and nine months ended September 30, 2025, all potentially dilutive shares in such periods were anti-dilutive, and therefore, excluded from the computation of diluted net loss per share.

The following is the computation of net (loss) income per common share for the three and nine months ended September 30, 2026 and 2025:

 

 

Three Months Ended
September 30,

 

For the Nine Months
Ended September 30,

 

 

2026

 

 

2025

 

2026

 

 

2025

 

Net (loss) income

 

$

642

 

 

$

(2,437

)

$

(2,307

)

 

$

(2,048

)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average basic common shares outstanding

 

 

6,482,408

 

 

 

6,322,078

 

 

6,410,477

 

 

 

6,271,229

 

Dilutive effect of options, restricted stock units and warrants

 

 

33

 

 

 

—

 

 

—

 

 

 

—

 

Weighted-average diluted common shares outstanding

 

 

6,482,441

 

 

 

6,322,078

 

 

6,410,477

 

 

 

6,271,229

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income per share:

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.10

 

 

$

(0.39

)

$

(0.36

)

 

$

(0.33

)

Diluted

 

$

0.10

 

 

$

(0.39

)

$

(0.36

)

 

$

(0.33

)

 

To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net income (loss) per share.

 

 

As of September 30,

 

 

2026

 

 

2025

 

Options to purchase common stock

 

 

131

 

 

 

131

 

Restricted stock units

 

 

33

 

 

 

98

 

Warrants to purchase common stock

 

 

10,022

 

 

 

10,022

 

 

10. Fair Value Measurements

20


Table of Contents

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

Assets and liabilities measured at fair value on a recurring basis as of September 30, 2026 are as follows:

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Contingent consideration

 

$

5,351

 

 

$

—

 

 

$

—

 

 

$

5,351

 

Total financial liabilities

 

$

5,351

 

 

$

—

 

 

$

—

 

 

$

5,351

 

 

The first $1,000 Phase 2 milestone obligation was settled through the issuance of common stock on July 31, 2026 and is excluded from the September 30, 2026 closing contingent consideration balance. See Note 5 for the gain on settlement of accounts payable recognized on the share settlement. The remaining milestone obligations were measured using a probability-weighted discounted cash flow model. Management’s September 30, 2026 assessment estimated their total fair value at $5,351.

Assumptions utilized in the valuation of Level 3 liabilities are described as follows:

 

 

As of September 30, 2026

 

Milestone

 

Probability Of Success

 

 

Payment Date

 

Discount Rate

 

1

 

 

100.0

%

 

7/31/2026

 

NA

 

2

 

 

11.7

%

 

12/31/2027

 

 

9.54

%

3

 

 

10.8

%

 

6/30/2029

 

 

9.54

%

4

 

 

10.8

%

 

6/30/2029

 

 

9.54

%

5

 

 

10.8

%

 

12/31/2031

 

 

14.54

%

6

 

 

10.8

%

 

12/31/2032

 

 

14.54

%

7

 

 

10.8

%

 

12/31/2033

 

 

14.54

%

 

 

 

 

Nine Months Ended September 30, 2026

 

 

Year Ended December 31, 2025

 

Contingent consideration

 

 

 

 

 

 

Beginning balance

 

$

6,799

 

 

$

—

 

Contingent consideration assumed in the GPCR USA acquisition

 

 

—

 

 

 

5,246

 

Payment by way of issue of common shares

 

 

(1,000

)

 

 

—

 

Change in fair value of contingent consideration

 

 

(448

)

 

 

1,553

 

Ending balance

 

$

5,351

 

 

$

6,799

 

 

At December 31, 2025, the current portion of contingent consideration of $995 was included in accrued expenses and other current liabilities. At September 30, 2026, the contingent consideration of $5,351 is presented as a noncurrent liability. On October 29, 2026, the Company entered into an agreement with GPCRT pursuant to which GPCRT agreed to reimburse the Company for certain research and development and other costs incurred by the Company on behalf of GPCR USA. The

21


Table of Contents

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

reimbursable costs include amounts incurred during September and October 2026. On October 28, 2026, the Company invoiced GPCRT approximately $142 for the applicable costs incurred during September and October 2026.

Cash and cash equivalents were measured using level 1 inputs as of September 30, 2026. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the period ended September 30, 2026 and the year ended December 31, 2025. The carrying amount of the Company’s receivables and payables approximate their fair value due to their maturity.

The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments. The Company uses the income approach and Level 3 inputs to value its liabilities. There were no liabilities, except for contingent consideration liability, measured at fair value on a recurring basis as of September 30, 2026.

11. Commitments and Contingencies

The Company is subject to various claims and legal actions that arise in the ordinary course of business. Management, after consultation with legal counsel, believes that the resolution of these matters will not have a material adverse effect on the Company’s financial position, results of operations, or cash flows.

On March 3, 2026, the Company received a Three Day Notice to Pay Rent or Quit from Dren Bio demanding payment of unpaid rent payments of approximately $0.7 million in connection with the sublease of its facilities situated in Redwood City or in the alternative quit and deliver up possession of the premises. Following receipt of such notice, the Company did not remit a payment and on March 9, 2026, Dren Bio filed a Complaint for Unlawful Detainer against GPCR USA in the Superior Court of California, County of San Mateo, seeking restitution of possession of the premises and forfeiture of the sublease and the unpaid rent payments of approximately $0.7 million, damages and attorney’s fees. The Company vacated the facility in Redwood City as of April 15, 2026. The Company is evaluating its legal and factual defenses and the potential financial impact of the matter. At this time, management cannot reasonably estimate any additional loss, if any, beyond amounts currently accrued in the Company’s condensed consolidated financial statements. Under the Asset Purchase Agreement, GPCR USA would retain its obligations to Dren Bio after closing.

The Company and certain of its current and former officers and directors were defendants in Colwell v. Exicure, Inc. et al., a securities class action in the United States District Court for the Northern District of Illinois (Case No. 1:21-cv-06637) (the “Securities Class Action”). On May 26, 2023, the plaintiffs filed a second amended complaint generally alleging that the defendants made false statements about the results of experiments concerning the drug XCUR-FXN and asserting claims for violations of federal securities laws under Section 10(b) and Section 20(a) of the Exchange Act and Rule 10b-5 thereunder. On October 8, 2024, the court granted preliminary approval of the settlement in the Securities Class Action and set a schedule for final approval proceedings, including a final approval hearing on January 13, 2025. On January 13, 2025, the court entered final judgment approving a settlement of this litigation, which settlement included a $5.625 million payment. The settlement was funded by the Company’s insurers, subject to certain agreements between the Company and the insurers.

The settlement described above was fully covered by insurance. However, the settlement includes a reservation of rights by the insurers against the Company for the unsatisfied portion of its self-insured retainer. As a result, the Company recorded an accrual as of September 30, 2024 for the amount of the unsatisfied retainer of approximately $1.1 million needed

22


Table of Contents

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

to bridge the $2.5 million retainer that the Company is liable for under its self- insured retention. On July 29, 2025, the Company entered into an agreement with the insurer to remit $1 million in order to satisfy the remaining balance of its self-insured retention obligation and paid this on August 13, 2025.

Three related stockholder derivative lawsuits were filed against certain of the Company’s current and former officers and directors and against the Company as a nominal defendant between March and April 2022 in the United States District Court for the Northern District of Illinois (Puri v. Giljohann, et al. (Case No. 1:22-cv-01083); Sim v. Giljohann, et al. (Case No. 1:22-cv-01217)), and the United States District Court for the District of Delaware (Stourbridge Investments LLC v. Exicure, Inc. et al. (Case No. 1:22-cv-00526)) (collectively, the “Derivative Complaints”). On March 18, 2022, James McNabb, through counsel, sent a written demand to the Company (the “Demand Letter”) demanding that the Board investigate certain allegations and commence proceedings on the Company’s behalf against certain of the Company’s officers and directors for alleged breaches of fiduciary duties and corporate waste. On March 18, 2026, the parties executed a formal settlement agreement. On June 2, 2026, the United States District Court for the Northern District of Illinois granted final approval of the global settlement and, on the same day, entered an order dismissing with prejudice the derivative litigation pending in that court pursuant to the settlement. On June 15, 2026, the United States District Court for the District of Delaware entered an order dismissing with prejudice the derivative litigation pending in that court pursuant to the settlement.

On October 3, 2023, a former employee filed a complaint against the Company and various of its former executives in the United States District Court for the District of New Jersey. The complaint is primarily a breach of contract claim relating to the former employee’s separation from the Company, as well as a claim for unpaid wages under the Illinois Wage Payment and Collection Act (“IWPCA”). On July 15, 2026, the parties entered into a settlement agreement in the amount of $425,000.

12. Related-Party Transactions

On February 1, 2025, the Company and Paul Kang came to an understanding that they would execute an agreement (the “Consulting Agreement”) by which Mr. Kang would provide transitional consulting services to the Company for the next 12 months. The Consulting Agreement between the Company and Alta Companies LTD (“Alta”) was executed on February 27, 2025. The Company paid Alta $99,000 after execution of the agreement and began paying Mr. Kang $12,500 monthly in February 2025. Mr. Kang is the President of Alta and was a director and officer of the Company through early 2025. He was a director from February 2023 to March 2025, and he was the CEO of the Company from August 2023 to January 2025.

 

 

13. Subsequent Events

On November 4, 2026, the Company and its wholly-owned subsidiary, GPCR USA, entered into an Intellectual Property, Asset and License Assignment Agreement (the “Asset Purchase Agreement”) with GPCRT, a Korean corporation. Under the Asset Purchase Agreement, the Company and GPCR USA agreed to sell to GPCRT substantially all of the assets relating to the GPC-100 (Burixafor) program and transfer certain related liabilities upon closing. These include the Company’s rights under its License and Collaboration Agreement with GPCR dated January 19, 2025, together with related intellectual property, clinical and regulatory data, assigned contracts, goodwill, contingent consideration and other liabilities related to GPC-100 program. The aggregate purchase price is KRW 6,500,000,000, estimated to be approximately $4,810,

23


Table of Contents

EXICURE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

payable in cash as follows: (i) a KRW 500,000,000, estimated to be approximately $371, deposit previously paid under a memorandum of understanding dated August 25, 2026 and presented under accrued expenses and other current liabilities in the accompanying consolidated balance sheets; (ii) a KRW 2,000,000,000, estimated to be approximately $1,480, interim payment due on or before November 16, 2026; and (iii) KRW 4,000,000,000, estimated to be approximately $2,959 at closing. As of the date these condensed consolidated financial statements were issued, the interim payment had not been received, and the parties are negotiating revisions to the terms and structure of the transaction, including the total purchase price and the timing of payments. GPCRT will also assume specified liabilities of the GPC-100 program incurred on or after September 1, 2026. No shares of GPCR USA are being sold, and GPCR USA will remain a wholly-owned subsidiary of the Company. Closing is subject to conditions, including approval by the parties’ boards of directors, consents and a waiver from GPCR, required third-party and regulatory approvals, and any required stockholder approval. There can be no assurance that the transaction will be completed on the terms described or at all. The parties may agree to revise its terms or structure, and the Company will disclose any such revision as required. For additional information, see the Company’s Current Report on Form 8-K filed on November 10, 2026.

On October 29, 2026, the Company entered into an agreement with GPCRT pursuant to which GPCRT agreed to reimburse the Company for certain research and development and other costs incurred by the Company on behalf of GPCR USA. The reimbursable costs include amounts incurred during September and October 2026. On October 28, 2026, the Company invoiced GPCRT approximately $142 for the applicable costs incurred during September and October 2026.

On November 20, 2026, the Company entered into a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. ("NeuroQ") and Laonz Co., Ltd. ("Laonz"), each a Korean corporation. NeuroQ holds the X-CUE business, a smart-glasses technology designed to assist patients with Parkinson's disease. Under the agreement, the parties intend to pursue the acquisition by the Company of an equity interest of 20% to 100% in NeuroQ, primarily through the acquisition of NeuroQ shares held by Laonz in exchange for newly issued shares of the Company's common stock. Following closing of the share acquisition, the Company intends to provide NeuroQ with development funding of up to $500. The final acquisition percentage, share exchange ratio, number of shares to be issued and closing date have not been determined. Completion of the share acquisition is subject to mutual written agreement on these terms, due diligence, and required corporate, stockholder, regulatory and Nasdaq approvals. There can be no assurance that the share acquisition will be completed.

24


Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following information should be read in conjunction with our unaudited condensed consolidated financial statements and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K (the “Annual Report”) for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission, or SEC, on March 25, 2026. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act, that involve significant risks and uncertainties. Our actual results, performance or experience could differ materially from what is indicated by any forward-looking statement due to various important factors, risks, uncertainties, assumptions and other factors including, but not limited to, those identified in this Quarterly Report on Form 10-Q and in our other SEC filings.

Overview

Historically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following the acquisition of GPCR USA in January 2025 and changes in our ownership, board composition and management team, our activities have primarily focused on supporting GPCR USA’s clinical development programs, evaluating strategic alternatives and preserving capital.

We continue to evaluate acquisitions, financing opportunities and other strategic alternatives. On August 25, 2026, the Company and its wholly-owned subsidiary, GPCR USA ("We"), signed a memorandum of understanding concerning a possible sale of the GPC-100 program and related rights. The proposed cash price is KRW 6.5 billion, estimated to be approximately $4,810. On November 4, 2026, we entered into a definitive agreement to sell specified GPC-100 program assets to GPCRT. Closing is subject to the conditions described in Note 13. We received a refundable deposit of KRW 500 million, estimated to be approximately $371, presented under accrued expenses and other current liabilities in the accompanying consolidated balance sheets at September 30, 2026. The sale had not closed at quarter-end.

On January 19, 2025, we acquired all outstanding shares of GPCR Therapeutics USA Inc. (“GPCR USA”) from GPCR Therapeutics Inc., a Korean corporation (“GPCR”). In connection with the acquisition, we entered into a License and Collaboration Agreement with GPCR to develop and commercialize licensed technologies. The agreement provides for payments upon achievement of clinical, regulatory and sales milestones, as well as recurring royalties.

On January 16, 2026, submission of the Phase 2 clinical study report to the U.S. Food and Drug Administration triggered the first $1,000 milestone under the License and Collaboration Agreement. The trial evaluated GPC-100 and propranolol for stem cell mobilization in patients with multiple myeloma. Effective July 31, 2026, we settled the obligation by issuing 172,058 shares of common stock. The shares had a fair value of $276, or $1.60 per share, resulting in a gain on settlement of accounts payable of $724.

We sold KC Creation Co., Ltd., our former South Korean subsidiary, on November 24, 2025. Our results for the 2025 comparative periods include KC Creation while it was a subsidiary.

Operating, financing, and cash flow considerations

Since our inception in 2011, we have primarily funded our operations through sales of our securities, loans and collaborations.

25


Table of Contents

 

 

As of September 30, 2026, our cash and cash equivalents were approximately $1,225, compared to approximately $3,746 as of December 31, 2025. The decrease primarily reflects cash utilized to fund operating activities, support GPCR USA’s clinical development activities and satisfy public company compliance obligations. Our current liquidity may not be sufficient to fund operations for the next 12 months. As a result, there is substantial doubt about our ability to continue as a going concern. Additional financing will be needed to fund our ongoing operations and exploration of strategic alternatives and pursue any alternatives that we identify. Management continues to evaluate potential equity financings, strategic transactions, partnering opportunities and other capital-raising alternatives. If we are unable to raise capital, the Company could seek bankruptcy protection and/or cease operations, which may result in our stockholders receiving no or very little value in respect of their shares of our common stock.

We expect to seek financing through equity offerings. However, it may be difficult to obtain financing given our current condition and uncertainty over its future direction. Therefore, we may be unable to raise capital at all or on favorable terms. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to continue operations.

 

Recent Developments

Nasdaq Listing Requirements Deficiency Notices

On May 28, 2026, Nasdaq notified us that the late filing of our Form 10-Q for the quarter ended March 31, 2026 violated its periodic filing requirement. We filed the report on May 29, 2026. On June 5, 2026, Nasdaq confirmed that we had regained compliance with that requirement.

On June 5, 2026, Nasdaq separately notified us that our stockholders’ equity of $2,098 at March 31, 2026 was below the $2,500 minimum under Nasdaq Listing Rule 5550(b)(1). We submitted a compliance plan on July 30, 2026. On September 10, 2026, Nasdaq granted us until December 2, 2026 to complete our plan and publicly demonstrate compliance. At September 30, 2026, we had a stockholders’ equity of $1,895.

If we do not meet the terms of the extension, Nasdaq may issue a delisting determination, which we would have the right to appeal to a Nasdaq Hearings Panel.

 

Critical Accounting Estimates

We prepare our condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, which require our management to make estimates that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.

We consider an accounting estimate to be critical if: (1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (2) changes in the estimate that are

26


Table of Contents

 

reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. There are items within our condensed consolidated financial statements that require estimation but are not deemed critical, as defined above.

Management has discussed the development and selection of these critical accounting estimates with the Audit Committee of our Board of Directors. Changes in estimates used in these and other items could have a material impact on our condensed consolidated financial statements. This includes estimates where the nature of the estimate is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and the impact of the estimate on financial condition or operating performance is material.

Business Combinations

We follow the acquisition method of accounting to record identifiable assets acquired and liabilities assumed or recognized in connection with acquired businesses at their estimated fair value as of the date of acquisition. Identifiable intangible assets from business combinations are recognized at their estimated fair values as of the date of acquisition and consist of in-process research and development (“IPR&D”). Determination of the estimated fair value of identifiable intangible assets requires judgment. The fair value of intangible assets is estimated using the Multi-Period Excess Earnings Method (MPEEM) for the acquired IPR&D. The fair value methods are income-based valuation approaches, which require judgment to estimate appropriate discount rates, probability of success rates related to the drug under development, projected revenue, gross margins, operating costs, and growth rates.

For the contingent consideration arising from the GPCR USA acquisition, we discount expected milestone payments using assumptions about the probability and timing of each payment and the applicable discount rate.

Estimates associated with the acquisition may change as additional information becomes available. The recoverability of the GPC-100 assets also depends on the estimated proceeds from the planned sale and the scope of assets and liabilities to be transferred.

 

Contingent Consideration

The contingent consideration liability associated with the GPCR USA acquisition is measured at fair value using significant unobservable inputs and is therefore classified as a Level 3 liability under ASC 820. The valuation incorporates management’s estimates regarding the probability and timing of achieving specified clinical, regulatory and commercial milestones, as well as appropriate discount rates. Changes in these assumptions could result in material changes in the fair value of the contingent consideration liability and corresponding gains or losses in future reporting periods. In connection with the planned disposition of the GPC-100 program, this liability would be assumed by GPCRT upon closing.

Results of Operations

Comparison of the three months ended September 30, 2026 and 2025

Period-to-period results include operating expenses and noncash effects of the July 31 milestone settlement and the September 30 contingent consideration remeasurement.

 

 

27


Table of Contents

 

The following table summarizes the results of our operations for the three months ended September 30, 2026 and 2025:

 

Three Months Ended
September 30,

 

 

 

 

 

 

 

(dollars in thousands)

 

2026

 

 

2025

 

 

Change

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

—

 

 

$

—

 

 

 

—

 

 

— %

 

Total Revenue

 

 

—

 

 

 

—

 

 

 

—

 

 

— %

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expense

 

 

146

 

 

 

888

 

 

 

(742

)

 

 

(84

)%

General and administrative expense

 

 

624

 

 

 

1,499

 

 

 

(875

)

 

 

(58

)%

Loss (gain) on disposal of assets

 

 

—

 

 

 

4

 

 

 

(4

)

 

 

(100

)%

Total operating expenses

 

 

770

 

 

 

2,391

 

 

 

(1,621

)

 

 

(68

)%

Operating loss

 

 

(770

)

 

 

(2,391

)

 

 

1,621

 

 

 

(68

)%

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

Dividend income

 

 

1

 

 

 

27

 

 

 

(26

)

 

 

(96

)%

Interest income

 

 

—

 

 

 

29

 

 

 

(29

)

 

 

(100

)%

Gain on settlement of accounts payable

 

 

724

 

 

 

155

 

 

 

569

 

 

 

367

%

Change in fair value of contingent consideration liability

 

 

688

 

 

 

(246

)

 

 

934

 

 

 

(380

)%

Other (expense)

 

 

(1

)

 

 

(11

)

 

 

10

 

 

 

(91

)%

Total other income (expense), net

 

 

1,412

 

 

 

(46

)

 

 

1,458

 

 

NM

 

Net (loss) income before provision for income taxes

 

 

642

 

 

 

(2,437

)

 

 

3,079

 

 

 

(126

)%

Provision for income taxes

 

 

—

 

 

 

—

 

 

 

—

 

 

— %

 

Net (loss) income

 

$

642

 

 

$

(2,437

)

 

$

3,079

 

 

 

(126

)%

 

 

 

 

 

 

 

 

 

 

 

 

 

NM = Not Meaningful

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expense

The following table summarizes our research and development expenses incurred during the periods indicated:

 

 

Three Months Ended
September 30,

 

 

 

 

 

 

 

(dollars in thousands)

 

2026

 

 

2025

 

 

Change

 

Employee-related expense

 

$

133

 

 

$

320

 

 

$

(187

)

 

 

(58

)%

Clinical development programs expense

 

 

13

 

 

 

568

 

 

 

(555

)

 

 

(98

)%

Total research and development expense

 

$

146

 

 

$

888

 

 

$

(742

)

 

 

(84

)%

 

Research and development expense was $146 for the three months ended September 30, 2026, reflecting a decrease of $742, or 84% from research and development expense of $888 for three months ended September 30, 2025. The Company incurred research and development expense in 2025 after the acquisition of GPCR USA; however, the Company temporarily deferred certain operating expenses, including research and development expense, during the three months ended September 30, 2026 pending the Company’s restructuring and reorganization.

28


Table of Contents

 

General and administrative expense

 

 

Three Months Ended
September 30,

 

 

 

 

 

 

 

(dollars in thousands)

 

2026

 

 

2025

 

 

Change

 

General and administrative expense

 

$

624

 

 

$

1,499

 

 

 

(875

)

 

 

(58

)%

Full time employees

 

 

2

 

 

 

8

 

 

 

(6

)

 

 

(75

)%

 

General and administrative expense was $624 for the three months ended September 30, 2026, representing a decrease of $875 or 58%, from $1,499 for the three months ended September 30, 2025. The decrease for the three months ended September 30, 2026 was primarily attributable to reduced headcount, lower payroll-related costs and reduced expenditures on professional services and corporate administration activities.

Other income and expense

The Company recognized a gain of $688 related to the change in the fair value of its contingent consideration liability for the three months ended September 30, 2026, compared to a loss of $246 in the comparative period in 2025. The contingent consideration liability relates to the GPC-100 license.

For the three months ended September 30, 2026, the Company had dividend income of $1 and interest income of nil, whereas the Company reported dividend income of $27 and interest income of $29 for the three months ended September 30, 2025.

For the three months ended September 30, 2026, the Company also recognized a gain on settlement of accounts payable of approximately $724 on settlement of the Phase 2 milestone liability.

29


Table of Contents

 

 

Comparison of the Nine Months Ended September 30, 2026 and 2025

The following table summarizes the results of our operations for the nine months ended September 30, 2026 and 2025:

 

Nine Months Ended
September 30,

 

 

 

 

 

 

 

(dollars in thousands)

 

2026

 

 

2025

 

 

Change

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

—

 

 

$

—

 

 

 

—

 

 

— %

 

Total Revenue

 

 

—

 

 

 

—

 

 

 

—

 

 

— %

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expense

 

 

632

 

 

 

2,631

 

 

 

(1,999

)

 

 

(76

)%

General and administrative expense

 

 

2,804

 

 

 

5,230

 

 

 

(2,426

)

 

 

(46

)%

Loss on disposal of assets

 

 

28

 

 

 

90

 

 

 

(62

)

 

 

(69

)%

Gain on early lease termination

 

 

—

 

 

 

(5,974

)

 

 

5,974

 

 

 

(100

)%

Total operating expenses

 

 

3,464

 

 

 

1,977

 

 

 

1,487

 

 

 

75

%

Operating loss

 

 

(3,464

)

 

 

(1,977

)

 

 

(1,487

)

 

 

75

%

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

Dividend income

 

 

1

 

 

 

106

 

 

 

(105

)

 

 

(99

)%

Interest income

 

 

11

 

 

 

38

 

 

 

(27

)

 

 

(71

)%

Gain on settlement of accounts payable

 

 

724

 

 

 

346

 

 

 

378

 

 

 

109

%

Change in fair value of contingent consideration liability

 

 

448

 

 

 

(541

)

 

 

989

 

 

 

(183

)%

Other (expense)

 

 

(27

)

 

 

(20

)

 

 

(7

)

 

 

35

%

Total other income (loss), net

 

 

1,157

 

 

 

(71

)

 

 

1,228

 

 

 

(1730

)%

Net loss before provision for income taxes

 

 

(2,307

)

 

 

(2,048

)

 

 

(259

)

 

 

13

%

Provision for income taxes

 

 

—

 

 

 

—

 

 

 

—

 

 

— %

 

Net loss

 

$

(2,307

)

 

$

(2,048

)

 

$

(259

)

 

 

13

%

 

 

Research and development expense

The following table summarizes our research and development expenses incurred during the periods indicated:

 

 

Nine Months Ended
September 30,

 

 

 

 

 

 

 

(dollars in thousands)

 

2026

 

 

2025

 

 

Change

 

Employee-related expense

 

$

577

 

 

$

746

 

 

$

(169

)

 

 

(23

)%

Clinical development programs expense

 

 

55

 

 

 

1,885

 

 

$

(1,830

)

 

 

(97

)%

Total research and development expense

 

$

632

 

 

$

2,631

 

 

$

(1,999

)

 

 

(76

)%

 

Research and development expense was $632 for the nine months ended September 30, 2026, reflecting a decrease of $1,999, or 76% from research and development expense of $2,631 for nine months ended September 30, 2025. The Company incurred research and development expense in 2025 after the acquisition of GPCR USA; however, the Company temporarily deferred certain operating expenses, including research and development expense, during the nine months ended September 30, 2026 pending the Company’s restructuring and reorganization.

General and administrative expense

 

Nine Months Ended
September 30,

 

 

 

 

 

 

 

(dollars in thousands)

 

2026

 

 

2025

 

 

Change

 

General and administrative expense

 

$

2,804

 

 

$

5,230

 

 

 

(2,426

)

 

 

(46

)%

Full time employees

 

 

2

 

 

 

8

 

 

 

(6

)

 

 

(75

)%

 

30


Table of Contents

 

 

General and administrative expense was $2,804 for the nine months ended September 30, 2026, representing a decrease of $2,426 or 46%, from $5,230 for the nine months ended September 30, 2025. The decrease for the nine months ended September 30, 2026 was due to the decreased number of full time employees and professional services compared to the same prior-year period.

Gain on early lease termination

Due to the early termination of the Chicago Lease as of January 31, 2025, the Company recognized a $5,974 gain resulting from the reversal of the remaining liability related to this lease for the nine months ended September 30, 2025. Accordingly, period-to-period comparisons of operating results are significantly affected by this one-time, non-recurring gain. Excluding the lease termination gain, operating losses improved primarily as a result of reductions in headcount, professional services costs and clinical development expenditures.

Other income and expense

The Company recognized a gain of $448 related to the change in the fair value of its contingent consideration liability for the nine months ended September 30, 2026 compared to a loss of $541 in the comparative period in 2025. The contingent consideration liability relates to the GPC-100 license.

For the nine months ended September 30, 2026, the Company reported dividend and interest income of $1 and $11, respectively, whereas the Company reported dividend income of $106 and interest income of $38 for the nine months ended September 30, 2025.

For the nine months ended September 30, 2026, the Company also recognized a gain on settlement of accounts payable of approximately $724 on settlement of the Phase 2 milestone liability.

 

Liquidity and Capital Resources

Since our inception, we have incurred significant operating losses. We generated limited revenue from our collaboration agreements, which have since been terminated. We have funded our operations to date with proceeds received from equity financings and payments received in connection with collaboration agreements, which have since been terminated. Currently we are evaluating strategic alternatives and did not generate revenue during the nine months ended September 30, 2026. As of September 30, 2026, our cash and cash equivalents were $1,225.

We incurred net loss of approximately $2,307 for the nine months ended September 30, 2026 and a loss of $2,048 for the nine months ended September 30, 2025. We expect to incur significant expenses and negative cash flows for the foreseeable future.

Our current liquidity is not sufficient to continue to fund existing obligations and operations. As a result, there is substantial doubt about our ability to continue as a going concern. Additional financing will be needed to fund our ongoing operations and exploration of strategic alternatives and pursue any alternatives that we identify. We may need to seek bankruptcy protection and/or cease operations in the near term, which may result in our stockholders receiving no or very little value in respect of their shares of our common stock.

See “Funding Requirements” below for additional information on our future capital needs.

Cash Flows

31


Table of Contents

 

The following table shows a summary of our cash flows for the nine months ended September 30, 2026 and 2025:

 

 

Nine Months Ended
September 30,

 

(in thousands)

 

2026

 

 

2025

 

 

(unaudited)

 

Net cash used in operating activities

 

$

(2,521

)

 

$

(7,408

)

Net cash used in investing activities

 

 

—

 

 

 

(2,262

)

Net cash provided by financing activities

 

 

—

 

 

 

1,600

 

Net decrease in cash and cash equivalents

 

$

(2,521

)

 

$

(8,070

)

 

Operating activities

Net cash used in operating activities was $2,521 and $7,408 for the nine months ended September 30, 2026 and 2025, respectively. The decrease in cash used in operating activities for the nine months ended September 30, 2026 of $4,887 was due to the Company’s reduced spending and reduced number of employees, to conserve cash during the restructuring and reorganization.

Investing activities

Net cash used in investing activities was nil and $2,262 for the nine months ended September 30, 2026 and 2025, respectively. The cash used by investing activities of $2,262 for the prior year was due to the purchase of GPCR USA. The Company did not have any investing activities for the current year.

Financing activities

Net cash provided by financing activities was nil and $1,600 for nine months ended September 30, 2026 and 2025, respectively. The $1,600 provided by financing activities in the prior year is due to the funds received from the common stock purchase agreements during the nine months ended September 30, 2025. The Company did not have any financing activities during the nine months ended September 30, 2026.

Funding Requirements

Our existing cash and cash equivalents are insufficient to meet our obligations and fund ongoing operating expenses for the twelve months following issuance of these financial statements. Our future capital requirements will depend on several factors, including the following.

•
the timing and proceeds of any sale of the GPC-100 assets and the outcome of other strategic initiatives,
•
the outcome of pending or future litigation,
•
the effect of inflation, interest rates, exchange rates and other economic conditions on our costs, and
•
the legal, accounting, regulatory and administrative costs of operating as a public company.

Based on our current cash position and operating forecasts, we will require additional capital to continue operations, satisfy existing obligations and execute our strategic objectives. There can be no assurance that such financing will be available when needed or on acceptable terms.

32


Table of Contents

 

We expect to rely primarily on equity offerings to finance our cash needs. Sales of equity or convertible debt would dilute existing stockholders, and the securities could carry liquidation or other preferences. Debt or preferred equity financing could restrict our ability to borrow, make capital expenditures or pay dividends. Capital market conditions may limit our ability to obtain financing on acceptable terms.

Going Concern

Our limited cash, recurring operating losses and lack of revenue raise substantial doubt about our ability to continue as a going concern for one year after issuance of the financial statements. We are pursuing additional financing and strategic transactions, including the proposed sale of the GPC-100 assets. The timing and amount of any additional proceeds remain uncertain.

Contractual Obligations and Commitments

There have been no material changes to our contractual obligations and commitments from those described in our Annual Report.

 

33


Table of Contents

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

Item 4. Controls and Procedures.

Limitations on Effectiveness of Controls

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), are designed to provide reasonable assurance that information required in our Exchange Act reports is recorded, processed, summarized and reported within the periods specified by the SEC and communicated to management, including our principal executive officer and principal financial officer, in time to make disclosure decisions.

 

Our management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026. Based on the evaluation of our disclosure controls and procedures as of September 30, 2026, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weakness described below.

Material Weakness in Internal Control Over Financial Reporting

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.

Management identified material weaknesses in the Company’s internal control over financial reporting related to the following:

1.
Management’s review of the accounting treatment of non-routine activities.
2.
The Company failed to design and implement controls around all accounting and information technology processes and procedures.

These matters have been reviewed with our Audit Committee.

 

34


Table of Contents

 

Remediation Plan

We are evaluating the material weakness and are developing a plan of remediation to strengthen the effectiveness of the design and operation of our internal control environment. The remediation plan will include enhancing our review procedures within our accounting department, implementing additional review procedures with respect to accumulation and evaluation of information that is known or knowable to the Company at the time, and applying that information to the applicable accounting guidance. Subject to our ability to obtain additional financing and the results of our review of strategic alternatives, we will also consider whether additional personnel are necessary.

Changes in Internal Control over Financial Reporting

Other than described above, there were no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

35


Table of Contents

 

PART II – OTHER INFORMATION

The Company is subject to various claims and legal actions that arise in the ordinary course of business. Management, after consultation with legal counsel, believes that the resolution of these matters will not have a material adverse effect on the Company’s financial position, results of operations, or cash flows.

On March 3, 2026, the Company received a Three Day Notice to Pay Rent or Quit from Dren Bio demanding payment of unpaid rent payments of approximately $0.7 million in connection with the sublease of its facilities situated in Redwood City or in the alternative quit and deliver up possession of the premises. Following receipt of such notice, the Company did not remit a payment and on March 9, 2026, Dren Bio filed a Complaint for Unlawful Detainer against GPCR USA in the Superior Court of California, County of San Mateo, seeking restitution of possession of the premises and forfeiture of the sublease and the unpaid rent payments of approximately $0.7 million, damages and attorney’s fees. The Company vacated the facility in Redwood City as of April 15, 2026. The Company is evaluating its legal and factual defenses and the potential financial impact of the matter. At this time, management cannot reasonably estimate any additional loss, if any, beyond amounts currently accrued in the Company’s condensed consolidated financial statements. Under the Asset Purchase Agreement, GPCR USA would retain its obligations to Dren Bio after closing.

The Company and certain of its current and former officers and directors were defendants in Colwell v. Exicure, Inc. et al., a securities class action in the United States District Court for the Northern District of Illinois (Case No. 1:21-cv-06637) (the “Securities Class Action”). On May 26, 2023, the plaintiffs filed a second amended complaint generally alleging that the defendants made false statements about the results of experiments concerning the drug XCUR-FXN and asserting claims for violations of federal securities laws under Section 10(b) and Section 20(a) of the Exchange Act and Rule 10b-5 thereunder. On October 8, 2024, the court granted preliminary approval of the settlement in the Securities Class Action and set a schedule for final approval proceedings, including a final approval hearing on January 13, 2025. On January 13, 2025, the court entered final judgment approving a settlement of this litigation, which settlement included a $5.625 million payment. The settlement was funded by the Company’s insurers, subject to certain agreements between the Company and the insurers.

The settlement described above was fully covered by insurance. However, the settlement includes a reservation of rights by the insurers against the Company for the unsatisfied portion of its self-insured retainer. As a result, the Company recorded an accrual as of September 30, 2024 for the amount of the unsatisfied retainer of approximately $1.1 million needed to bridge the $2.5 million retainer that the Company is liable for under its self- insured retention. On July 29, 2025, the Company entered into an agreement with the insurer to remit $1 million in order to satisfy the remaining balance of its self-insured retention obligation and paid this on August 13, 2025.

Three related stockholder derivative lawsuits were filed against certain of the Company’s current and former officers and directors and against the Company as a nominal defendant between March and April 2022 in the United States District Court for the Northern District of Illinois (Puri v. Giljohann, et al. (Case No. 1:22-cv-01083); Sim v. Giljohann, et al. (Case No. 1:22-cv-01217)), and the United States District Court for the District of Delaware (Stourbridge Investments LLC v. Exicure, Inc. et al. (Case No. 1:22-cv-00526)) (collectively, the “Derivative Complaints”). On March 18, 2022, James McNabb, through counsel, sent a written demand to the Company (the “Demand Letter”) demanding that the Board investigate certain allegations and commence proceedings on the Company’s behalf against certain of the Company’s officers and directors for alleged breaches of fiduciary duties and corporate waste. On March 18, 2026, the parties executed a formal settlement agreement. On June 2, 2026, the United States District Court for the Northern District of Illinois granted final

36


Table of Contents

 

approval of the global settlement and, on the same day, entered an order dismissing with prejudice the derivative litigation pending in that court pursuant to the settlement. On June 15, 2026, the United States District Court for the District of Delaware entered an order dismissing with prejudice the derivative litigation pending in that court pursuant to the settlement.

On October 3, 2023, a former employee filed a complaint against the Company and various of its former executives in the United States District Court for the District of New Jersey. The complaint is primarily a breach of contract claim relating to the former employee’s separation from the Company, as well as a claim for unpaid wages under the Illinois Wage Payment and Collection Act (“IWPCA”). On July 15, 2026, the parties entered into a settlement agreement in the amount of $425,000.

General

We may also be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors.

The sale of the GPC-100 program would dispose of our principal operating program. If we complete the sale before establishing another operating business, our ability to continue operations and maintain our Nasdaq listing could be adversely affected. The proposed transaction remains subject to approvals by the parties’ boards of directors, consents and a waiver from GPCR, required third-party and regulatory approvals, and any required stockholder approval. If the sale does not close, we may have to return the deposit, continue funding the program and obtain capital from other sources.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On July 31, 2026, we issued 172,058 shares of common stock to GPCR Therapeutics Inc. in satisfaction of the $1,000 milestone obligation under the License and Collaboration Agreement. We received no cash proceeds from the issuance.


37


Table of Contents

 

Item 6. Exhibits

 

 

 

 

 

Incorporated by Reference

Exhibit No.

 

Exhibit Description

 

Form

 

Exhibit No.

 

Filing Date

 

File No.

3.1

 

Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on November 15, 2017.

 

10-K

 

3.3

 

3/11/21

 

001-39011

 

 

 

 

 

 

 

 

 

 

 

3.2

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Exicure, Inc., effective June 29, 2022.

 

8-K

 

3.1

 

06/29/22

 

001-39011

 

 

 

 

 

 

 

 

 

 

 

3.3

 

Amended and Restated Bylaws, as currently in effect.

 

8-K

 

3.4

 

10/02/17

 

000-55764

 

 

 

 

 

 

 

 

 

 

 

3.4

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Exicure, Inc., effective August 27, 2024

 

8-K

 

3.1

 

8/26/24

 

001-39011

 

 

 

 

 

 

 

 

 

 

 

31.1*

 

Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31.2*

 

Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

32.1**

 

Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.INS*

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH*

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL*

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF*

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB*

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE*

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

104*

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

 

 

 

 

 

* Filed herewith.

** The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exicure, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.

38


Table of Contents

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 20, 2026

 

EXICURE, INC.

 

 

By:

/s/ Jung Soo Kim

 

Jung Soo Kim

 

Chief Executive Officer

 

 

By:

/s/ Gyuyeob Lee

 

Gyuyeob Lee

 

Chief Financial Officer

 

39


Keep reading